Turn Therapeutics Inc. (TTRX) - Form 8-K Summary
Business Context and Reporting Period
Turn Therapeutics Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 31, 2026. The filing serves to announce the company's financial and operating results for the fiscal year ended December 31, 2025, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced Press Release (Exhibit 99.1), which is not included in the source text provided for this summary.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of results for the year ended December 31, 2025.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the accompanying Press Release shall not be deemed "filed" under Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings except as expressly set forth. No specific guidance, outlook, or risk factors are detailed within the body of this 8-K text.
Investor Verification Checklist
- Review the full text of the Press Release (Exhibit 99.1) for specific financial figures for the year ended December 31, 2025.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (TTRX) and exchange (The Nasdaq Stock Market LLC) for current market data.
- Check subsequent filings for any updates to the financial results announced in this report.